Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and eff
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... July 10, 2014 Decision Resources Group finds ... the U.S. Food and Drug Administration,s (FDA) approval of ... Velphoro, which was approved by the FDA in November ... disease (CKD) patients on dialysis. Other key ... (US) Q2 2014 : ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Inc., announced today that it acquired all U.S. rights ... Denavir® owned by Novartis.  Denavir (1% penciclovir cream) is ... for the treatment of recurrent herpes labialis (cold sores) ... older.  The topical antiviral cream market in the U.S. ...
... 1 A web-based tool that extracts information from the ... and manage their entire panel of patients. Those are the ... to examine the effectiveness of a panel management tool in ... study, published today in The American Journal of Managed ...
Cached Medicine Technology:New American Therapeutics Acquires Antiviral Drug Denavir® 2Innovative Web-based Tool Helps Doctors Improve Care 2Innovative Web-based Tool Helps Doctors Improve Care 3Innovative Web-based Tool Helps Doctors Improve Care 4Innovative Web-based Tool Helps Doctors Improve Care 5
(Date:7/13/2014)... Micro irrigation systems are mainly utilized ... as wells as to maintain soil quality. The application ... become a dominant revenue generator for manufacturers in future. ... resource costs has led to the adoption of micro ... further caused massive demand for micro irrigation systems, as ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced that ... following investor conferences,in November and December:, Lazard Capital ... 2 East 55th Street, New York Presentation: ... Annual Piper Jaffray Health Care Conference The New York ...
... blood flow , , TUESDAY, Nov. 11 (HealthDay News) -- Throw ... back and relax in the knowledge that your blood vessels ... , Nothing could be healthier for your heart, a new ... good may also be a good preventive measure for heart ...
... Nov. 11 Anthem Blue Cross and,Blue Shield in ... 239 health,insurance plans, according to the current (Nov. 17) ... Plans 2008-09. This recognition as,one of the nation,s best ... clinical care measures, member satisfaction and NCQA,accreditation., "We ...
... carry cholesterol and triglycerides throughout the body , , TUESDAY, ... particles may increase the risk of high blood pressure ... That,s the conclusion of a new study by U.S. ... the Women,s Health Study. , Lipoprotein particles carry cholesterol ...
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... Southwestern Medical Center have uncovered new insights into the "Dr. ... stem-cell maturation in the brain but, paradoxically, can also lead ... mice scheduled to appear online this week and in an ... of Sciences , UT Southwestern research teams studied the protein ...
Cached Medicine News:Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 2Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 3Health News:Joyful Music in Tune With Heart Health 2Health News:Joyful Music in Tune With Heart Health 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 3Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 4Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 5Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 6Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 7Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 8Health News:Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance America's Best Health Plans List 9Health News:Lipoprotein Levels May Predict Women's Hypertension Risk 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 2Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 3
... switch control, solid cast aluminum frame, ... folding armrests, multi-position full range articulating ... handle, ergonomically contoured cushions with anti-viral ... of upholstery colors. Optional features: foot ...
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... HPX Streak Retinoscope comes ... and provides 40% more ... scopes and maintains a ... greatly enhances illumination and ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
Medicine Products: